Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database
Therapeutic Innovation & Regulatory Science · 2025-01 · 59 (1) · 135-141
DOI: 10.1007/s43441-024-00712-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 25.10.2024. Verfasst von Siyuan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, China. Hauptthemen laut MEDLINE: Denosumab, Hypocalcemia, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Medical Scientific Research Foundation of Guangdong.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Denosumab is widely used for osteoporosis and cancer treatment. However, hypocalcemia induced by denosumab is a frequent adverse event. The objective of this study is to comprehensively investigate the safety signals and the occurrence of hypocalcemia in real-world patient cases reported through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). METHODS: Reports from January 1, 2017 to December 31, 2021 were extracted from the FAERS. Only cases of hypocalcemia suspected to denosumab were eligible in pharmacovigilance study. Denosumab-related hypocalcemia safety signal were identified to characterize their clinical features. A safety signal for hypocalcemia was evaluated using reporting odds ratios (ROR). RESULTS: Among the 102,413 cases related to denosumab, 1042 cases were reported with denosumab-related hypocalcemia. The affected patients were mainly elderly (median age 70 years) and male (n = 568, 63.5%). In available data, the median onset time of 23 (range 0-1601) days. Most patients required drug interruption (n = 226, 72.9%) and can achieve a recovered-resolved state (n = 318, 62.1%). For the whole database, denosumab exhibited a safety signal for hypocalcemia (ROR = 14.09, 95% Cl 13.18, 15.06). In the sensitivity analyses, denosumab also showed a safety signal for hypocalcemia in cancer (ROR = 21.28, 95% Cl 18.79, 24.11) and osteoporosis (ROR = 9.29, 95% Cl 6.80, 12.59). Compared with bisphosphonates, denosumab still has safety signal for hypocalcemia (ROR = 1.88, 95% Cl 1.67, 2.11). CONCLUSIONS: This pharmacovigilance database analysis indicates a high safety signal for hypocalcemia associated with denosumab, particularly in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, China.
- World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Reg…
- Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, China. hushijie@163.com.
Förderung
- Medical Scientific Research Foundation of Guangdong
Zitieren
APA
Gao, S., Zheng, G., He, Z., Chen, L., Yan, D., Lai, Z., Cai, T., & Hu, S. (2025). Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database. Therapeutic Innovation & Regulatory Science, 59(1), 135-141. https://doi.org/10.1007/s43441-024-00712-8
Vancouver
Gao S, Zheng G, He Z, Chen L, Yan D, Lai Z, et al. Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database. Therapeutic Innovation & Regulatory Science. 2025;59(1):135-141. doi:10.1007/s43441-024-00712-8
BibTeX
@article{Gao2025,
author = {Gao, Siyuan and Zheng, Guanhao and He, Zhichao and Chen, Lishi and Yan, Dengfeng and Lai, Zhisheng and Cai, Tingfeng and Hu, Shijie},
title = {Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2025},
volume = {59},
number = {1},
pages = {135--141},
doi = {10.1007/s43441-024-00712-8}
}
EUVIMED